The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
Zymeworks and longtime partner Merck signed a new license agreement. Merck was granted the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.
Gilead Sciences started an early-stage study of the company’s antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
The U.S. drug regulator declined to approve a combination of Merck & Co. Inc.’s blockbuster cancer drug Keytruda and Eisai Co. Ltd.’s Lenvima as the first line of treatment in patients with liver cancer.
IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes.
Cellectis announced that the U.S. Food and Drug Administration placed a clinical hold on the company’s MELANI-01 trial of UCARTCS1A for relapsed or refractory multiple myeloma (MM).
As the United States accelerates the search for a coronavirus vaccine, tensions have erupted between government scientists and Moderna Inc., one of the leading developers, Reuters has learned.
Britain’s GSK said an injection of the company’s cabotegravir drug given every two months was found to be 65 percent more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
